Type 2 Diabetes

Optimize Clinical Diabetes Management with AI Technology

A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs.

In part 3: user testimonials about the experience and exciting findings using the software. A more in-depth examination of the benefits of applying decision-support software in clinical practice.   

Collaborative Analysis Concludes that the AI Tool Improves Outcomes for Type 2 Diabetes Patients 

A new clinical software using artificial intelligence is being used for those with Type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature is a 3-part series. 

The project was designed to address through clinical intervention the issues experienced by patients with diabetes, such as high A1c levels. Through team-based care, clinical software support, and patient engagement, the intervention was projected to help control HbA1c and potentially lower treatment costs.  

A new clinical software using artificial intelligence is being used for those with type 2 diabetes in Kentucky. It shows promising results in improving the Quality of Life for its residents and lowering treatment costs. This feature will be a 3-part series. 

In Part 1:  Adherence-related issues are hemorrhaging the costs of diabetes-related treatment in America. To offset this tragedy, GlucosePATH is utilized by a team of healthcare professionals dedicated to improving the quality of life while decreasing avoidable costs.  

Cardiovascular events decline for patients using which antidiabetic medication?

The combination of an SGLT2i plus a GLP-1 RA results in surprising effects on endogenous glucose production and HBA1c. 

Is the risk as substantial as was initially reported?

The case for expanding screening for pancreatic cancer in those with new onset of diabetes and weight loss. 

In type 2 diabetes patients, treating diastolic function and myocardial perfusion reserve could improve aerobic exercise capacity and prevent heart failure. 

CoviDIAB Registry will explore why COVID-19 can increase complications in people with pre-existing diabetes, and may also be driving new cases. 

If dapagliflozin is the second medication prescribed to the patient after the first-line treatments of metformin or sulfonylurea, it has a greater impact.